AbbVie Slides as U.S. Agency Questions Humira Patent

Updated on
  • U.S. patent office agrees to consider a challenge by Coherus
  • The agency will review an AbbVie patent for the arthritis drug

One of AbbVie Inc.’s patents on its top-selling arthritis drug Humira may be invalid, a U.S. agency said, agreeing to consider a challenge filed by Coherus Biosciences Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.